Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

In conclusion, several Nifty 50 stocks, including Cipla, Sun Pharma and Infosys, experienced declines in Wednesday's trading ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

As global demand for next-generation therapies on diabetes and weight loss surges, Indian pharmaceutical companies are ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

The classification was communicated to the company via email on 4 August 2025. The inspection was conducted under the USFDA's ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, ...

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India. Despite category dominance and decades of trust, Cipla is now playing catch ...